Cytokine storm scale as a prognostic tool of course of viral pneumonia in COVID-19


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The aim of the study is to validate the cytokine storm scale (CSS) in a cohort of patients with COVID-19-associated pneumonia to confirm its diagnostic and informative value. Material and methods. The study included 48 patients with COVID-19-associated pneumonia who were admitted to hospital for treatment, and 73 intensive care unit (ICU) patients. The levels of interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 18 (IL-18), interleukin 10 (IL-10) and procalcitonin (PCT) were measured using enzyme immunoassay, and CSS was calculated. For each biomarker, grade marks were calculated in the range from 1 to 3: at the border concentration of the studied index, 1 grade mark was awarded, with an average - 2, with a high - 3 (normal values were corresponded to 0 marks). A CSS score of more than 6 was associated with a high risk of adverse COVID-19 outcome. Results. When assessing the informativeness of CSS indexes concerning mortality prediction, it was found that it had high sensitivity (78,79%; 95% CI: 0,61-0,91) and specificity (81,12%; 95% CI: 71,2488,80). Also CSS positively and statistically significantly correlated with the NEWS2 scale (0,58; 95% CI: 0,35-0,75), degree of pulmonary damage according to computer tomography data (0,46; 95% CI: 0,20-0,67 ) and the percentage of pulmonary tissue damage (0,38; 95% CI: 0,01-0,61). Conclusion. The developed CSS has a sufficiently high predictive information value in relation to the risk of an unfavorable prognosis of COVID-19 clinical course. The combined prognostic capabilities of the cytokines IL-6, IL-18, IL-10 and PCT, integrated into a single index, make it more likely to identify patients of high risk of death in case of COVID-19-associated pneumonia.

Толық мәтін

Рұқсат жабық

Авторлар туралы

O. Tkachenko

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: tkachenie0mail.ru
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

M. Pervakova

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: margaritalerner@gmail.com
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

S. Lapin

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: svlapin0mail.ru
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

A. Masing

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: alex_mazing0mail.ru
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

A. Moshnikova

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: moshnikova-anna@mail.ru
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

D. Kuznetsova

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: lariwar@mail.ru
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

I. Kholopova

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: irinakholopova@yandex.ru
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

T. Blinova

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: easurkova@mail.ru
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

E. Surkova

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: tvwinova@list.ru
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

Yu. Polushin

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: polushinyus@1spbgmu.ru
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

A. Afanasiev

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: alex-txf@mail.ru
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

I. Shlyk

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: egavrilova70@mail.ru
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

E. Gavrilova

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: irina_shlyk@mail.ru
197022, Saint Petersburg, 6/8 Lva Tolstogo Str. Tel.: +7 (812) 994-53-24, +7 (812) 338-71-94

E. Kornilova

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

Email: liza_kornilova@ьk.ru
191015, Saint Petersburg, 41 Kirochnaya Str. Tel.: +7 (921) 951-71-88

D. Ivannikova

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

Email: d.ivannikova@yandex.ru
191015, Saint Petersburg, 41 Kirochnaya Str. Tel.: +7 (921) 951-71-88

E. Trophimov

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

Email: evgeniy.trofimov@szgmu.ru
191015, Saint Petersburg, 41 Kirochnaya Str. Tel.: +7 (921) 951-71-88

V. Mazurov

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

Email: maz.nwgmu@yandex.ru
191015, Saint Petersburg, 41 Kirochnaya Str. Tel.: +7 (921) 951-71-88

Әдебиет тізімі

  1. Hu B., Guo H., Zhou P. et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021; 19(3): 141-54. doi: 10.1038/ s41579-020-00459-7.
  2. Guan W., Ni Z., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708-20. doi: 10.1056/NEJMoa2002032.
  3. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 395(10229): 1054-62. doi: 10.1016/S0140-6736(20)30566-3.
  4. Tay M.Z., Poh C.M., Renia L. et al. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol. 2020; 20(6): 363-74. doi: 10.1038/s41577-020-0311-8.
  5. Li C., Zhao C., Bao J. et al. Laboratory diagnosis of coronavirus disease-2019 (COVID-19). Clin Chim Acta. 2020; 510: 35-46. doi: 10.1016/j.cca.2020.06.045.
  6. Han H., Ma Q., Li C. et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020; 9(1): 1123-30. doi: 10.1080/22221751.2020.1770129.
  7. Fan G., Tu C., Zhou F. et al. Comparison of severity scores for COVID-19 patients with pneumonia: A retrospective study. Eur Respir J. 2020; 56(3): 2002113. doi: 10.1183/13993003.02113-2020.
  8. Ткаченко О.Ю., Первакова М.Ю., Лапин С.В. с соавт. Прогностическая роль исследования цитокинов при COVID-19-ассоциированной пневмонии. Вестник Северо-Западного государственного университета им. И.И. Мечникова. 2021; 1: 59-69. @@Tkachenko O.Y., Pervakova M.Y., Lapin S V. et al. Prognostic value of cytokines in COVID-19 associated pneumonia. Vestnik Severo-Zapadnogo gosudarstvennogo universiteta im. I.I. Mechnikova = Bulletin of the Northwestern State University named after I.I. Mechnikov. 2021; 1: 59-69 (In Russ.). doi: https://dx.doi.org/10.17816/mechnikov61610.
  9. Satis H., Ozger H.S., Aysert Yildiz P. et al. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19. Cytokine. 2021; 137: 155302. doi: 10.1016/j.cyto.2020.155302.
  10. Crayne C.B., Albeituni S., Nichols K.E. et al. The immunology of macrophage activation syndrome. Front Immunol. 2019; 10: 119. doi: 10.3389/fimmu.2019.00119.
  11. Qin C., Zhou L., Hu Z. et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71(15): 762-68. doi: 10.1093/cid/ciaa248.
  12. Jamilloux Y., Henry T., Belot A. et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020; 19(7): 102567. doi: 10.1016/j.autrev.2020.102567.
  13. Coomes E.A., Haghbayan H. Interleukin6 in COVID-19: A systematic review and meta-analysis. Rev Med Virol. 2020; 30(6): 1-9. doi: 10.1002/rmv.2141.
  14. Lauw F.N., Pajkrt D., Hack C.E. et al. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol. 2000; 165(5): 2783-89. doi: 10.4049/jimmunol.165.5.278.
  15. Lu L., Zhang H., Dauphars D.J. et al. A potential role of interleukin 10 in COVID-19 pathogenesis. Trends Immunol. 2021; 42(1): 3-5. doi: 10.1016/j.it.2020.10.012.
  16. Lippi G., Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020; 505: 190-91. doi: 10.1016/j.cca.2020.03.004.
  17. Song J., Park D.W, Moon S. et al. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infect Dis. 2019; 19(1): 968. doi: 10.1186/s12879-019-4618-7.
  18. Hu R., Han C., Pei S. et al. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020; 56(2): 106051. doi: 10.1016/j. ijantimicag.2020.106051.
  19. Vanska M., Koivula I., Jantunen E. et al. IL-10 combined with procalcitonin improves early prediction of complications of febrile neutropenia in hematological patients. Cytokine. 2012; 60(3): 787-92. doi: 10.1016/j.cyto.2012.07.023.
  20. Liang W., Liang H., Ou L. et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020; 180(8): 1081-89. doi: 10.1001/jamainternmed.2020.2033.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2021

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>